{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lebrikizumab", "query": { "intervention": "lebrikizumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lebrikizumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T01:56:49.193Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01545440", "title": "A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "lebrikizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 258, "start_date": "2012-03", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-03-05", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 70, "location_summary": "Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more", "locations": [ { "city": "Pell City", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01545440" }, { "nct_id": "NCT02340234", "title": "A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "TCS Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 212, "start_date": "2015-05", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 16, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340234" }, { "nct_id": "NCT04626297", "title": "A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 254, "start_date": "2020-11-17", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626297" }, { "nct_id": "NCT03443024", "title": "A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2018-01-30", "completion_date": "2019-05-23", "has_results": true, "last_update_posted_date": "2021-05-04", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 58, "location_summary": "Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03443024" }, { "nct_id": "NCT00441818", "title": "Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin's Lymphoma" ], "interventions": [ { "name": "TNX-650", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanox", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2006-05", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2008-05-09", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00441818" }, { "nct_id": "NCT01423318", "title": "A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "lebrikizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2011-08", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01423318" }, { "nct_id": "NCT06906497", "title": "Lebrikizumab in Moderate-to-severe Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "lebrikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johann E Gudjonsson MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2025-07-02", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 2, "location_summary": "Folsom, California • Ann Arbor, Michigan", "locations": [ { "city": "Folsom", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06906497" }, { "nct_id": "NCT01545453", "title": "A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "lebrikizumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 205, "start_date": "2012-03", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 62, "location_summary": "Oxford, Alabama • Long Beach, California • Los Angeles, California + 57 more", "locations": [ { "city": "Oxford", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01545453" }, { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT05369403", "title": "A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 86, "start_date": "2022-12-19", "completion_date": "2025-02-05", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-09-11T01:56:49.193Z", "location_count": 37, "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Fountain Valley, California + 31 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Laguna Niguel", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05369403" } ] }